Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857234 | 1.00 | CES2 (0.35) | CES2CES1MEN1CYP3A4ALOX15 | |
| SCHEMBL4857238 | 1.00 | CES2 (0.35) | CES2CES1MEN1CYP3A4ALOX15 | |
| SCHEMBL11858127 | 0.81 | CES2 (0.35) | CES2CES1ALDH1A1MGLLCTSK | |
| SCHEMBL11858131 | 0.81 | CES2 (0.35) | CES2CES1ALDH1A1MGLLCTSK | |
| SCHEMBL11506161 | 0.79 | ALDH1A1 (0.39) | CES2CES1ALDH1A1MGLL | |
| SCHEMBL11506163 | 0.79 | ALDH1A1 (0.39) | CES2CES1ALDH1A1MGLL | |
| SCHEMBL31538843 | 0.77 | EPHX1 (0.35) | CES2CES1 | |
| SCHEMBL26089586 | 0.76 | — | — | |
| SCHEMBL4866423 | 0.74 | CES2 (0.33) | CES2CES1ALDH1A1MGLL | |
| SCHEMBL4866439 | 0.74 | CES2 (0.33) | CES2CES1ALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-10029969-B2 | Method of producing optically-active aldehyde | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| EP-2966054-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | Takasago International Corporation (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376102-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20080125310-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-29 | — | — | US | disclosed |
| US-7323604-B2 | Hydride reduction of α,β-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-07-20 | — | — | US | disclosed |
| EP-0258967-B2 | Process for producing optically active alcohols | TAKASAGO PERFUMERY CO LTD (JP) | 1996-08-21 | — | — | EP | disclosed |
| US-4962242-A | HYDROGENATING OLEFINIC ALCOHOL USING AS CATALYST A RUTHENIUM-OPTICALLY ACTIVE PHOSPHINE COMPLEX | TAKASAGO PERFUMERY CO., LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0258967-A2 | Process for producing optically active alcohols | Takasago Perfumery Co., Ltd. (JP) | 1988-03-09 | — | — | EP | disclosed |
| US-3995054-A | MITICIDES | ZOECON CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029969-B2 | Method of producing optically-active aldehyde | ALDH3A1, ALDH1A2, ADH1A | CES2 296/4885CES1 574/4885MEN1 3945/4885 |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | ECH1, CBR1, DHCR24 | CES2 848/4885CES1 235/4885MEN1 4083/4885 |
| US-20150376102-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | ALDH3A1, ALDH1A2, ADH1A | CES2 296/4885CES1 574/4885MEN1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.